Biogen Inc.
BIIBBiogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).
Drugs in Pipeline
94
Phase 3 Programs
37
Upcoming Catalysts
9
Next Catalyst
This month
Market Overview
Stock performance and key metrics
9 upcoming, 0 past
How BIIB's past catalysts played out
Leqembi
Lecanemab
Alzheimer Disease
Tofersen
ALS (SOD1)
Omaveloxolone
Friedreich Ataxia
SAGE-217 15/20 mg Oral Solution
Postpartum Depression
BIIB041 (Fampridine-SR)
Multiple Sclerosis
Litifilimab
Lupus Erythematosus, Systemic
peginterferon beta-1a
Relapsing Multiple Sclerosis
Avonex
Multiple Sclerosis
Bardoxolone Methyl
Alport Syndrome
ALKS 8700
Relapsing Remitting Multiple Sclerosis
Natalizumab (BG00002)
Multiple Sclerosis
BIIB017 (peginterferon beta-1a)
Multiple Sclerosis, Relapsing-Remitting
Interferon Beta-1a
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
dimethyl fumarate
Relapsing-Remitting Multiple Sclerosis
Interferon Ξ²-1a
Relapsing-Remitting Multiple Sclerosis
Salanersen
Muscular Atrophy, Spinal
tonapofylline
Renal Insufficiency
Midazolam
Relapsing-Remitting Multiple Sclerosis
BIIB041 (fampridine)
Multiple Sclerosis, Remittent Progressive
natalizumab
Crohn's Disease
BIIB019 (Daclizumab High Yield Process)
Relapsing-Remitting Multiple Sclerosis
Diroximel fumarate
Relapsing Forms of Multiple Sclerosis
BG9418 (Interferon beta-1a)
Active Ulcerative Colitis
Glatiramer Acetate
Relapsing-Remitting Multiple Sclerosis
BG00012
Multiple Sclerosis
Anti-inflammatory drugs
Rheumatoid Arthritis
fampridine
Multiple Sclerosis
Felzartamab
Primary Membranous Nephropathy
BG00012 (dimethyl fumarate)
Healthy
lixivaptan
Hyponatremia
BG00002 (natalizumab)
Multiple Sclerosis, Relapsing-Remitting
Sertraline
Depressive Disorder, Major
Alefacept
Chronic Plaque Psoriasis
SAGE-217
Bipolar Disorder I
Mycophenolate Mofetil (cellcept)
Multiple Sclerosis
Nusinersen
Muscular Atrophy, Spinal
Rituxan, Cyclophosphamide, Vincristine, Prednisone
Immune Thrombocytopenic Purpura
baricitinib treatment
Rheumatoid Arthritis
BIIB017
Relapsing Multiple Sclerosis
Omaveloxolone Ophthalmic Suspension 0.5%
Corneal Endothelial Cell Loss
exemestane (Aromasin)
Breast Cancer
trivalent seasonal influenza vaccine
Relapsing-Remitting Multiple Sclerosis
BIIB122
Parkinson Disease
Methylprednisolone
Graft Versus Host Disease
Zevalin Radioimmunotherapy
Lymphoma
SAGE-324
Essential Tremor
CHOP
Non-Hodgkins Lymphoma
Y Zevalin
Lymphoma
Zevalin
Lymphoma
90Y Zevalin
Non-Hodgkins Lymphoma
Tyruko Injectable Product
Multiple Sclerosis
Transitioning patients from cyclosporine to alefacept
Psoriasis
Ibritumomab Tiuxetan (Zevalin)
Lymphoma
BIIB080
Alzheimer Disease
BIIB091
Relapsing Forms of Multiple Sclerosis
Omaveloxolone capsules, 2.5 mg
MItochondrial Myopathies
Bardoxolone methyl oral capsule
Chronic Kidney Diseases
CNV1014802
Lumbosacral Radiculopathy
BIIB104
Cognitive Impairment Associated With Schizophrenia
Lumiliximab with FCR
Chronic Lymphocytic Leukemia
BG9924
Rheumatoid Arthritis
BIIB021
GIST
BIIB041 (PR Fampridine)
Multiple Sclerosis
BG00010
Painful Lumbar Radiculopathy
BIIB014
Parkinson's Disease
BIIB112
X-Linked Retinitis Pigmentosa
Ad.hIFN-Ξ² (BG00001, IDEC-201)
Colorectal Carcinoma
BIIB033
Multiple Sclerosis
IDEC-114
Non-Hodgkin's Lymphoma
MOR202
Glomerulonephritis
Omaveloxolone Ophthalmic Suspension 1.0%
Inflammation and Pain Following Ocular Surgery
BIIB033 100mg/Kg
Acute Optic Neuritis
Bardoxolone methyl capsules
IgA Nephropathy
BIIB111
Choroideremia
Bardoxolone Methyl (RTA 402)
Chronic Kidney Disease
natalizumab IV
Relapsing-Remitting Multiple Sclerosis
BG00002-E (natalizumab high titer)
Multiple Sclerosis
tetanus diphtheria toxoids vaccine
Relapsing Forms of Multiple Sclerosis
Omaveloxolone Capsules (2.5 mg/capsule)
Melanoma
Baminercept alfa 1
Rheumatoid Arthritis
BIIB074
Primary Inherited Erythromelalgia
Omaveloxolone Capsules, 300 mg
Friedreich Ataxia
Omaveloxolone Lotion 0.5%
Breast Cancer
Bardoxolone methyl (amorphous dispersion)
Renal Insufficiency, Chronic
RTA 402 (Bardoxolone Methyl)
Diabetic Nephropathy
BIIB059 (litifilimab)
Systemic Lupus Erythematosus
BG00011
Idiopathic Pulmonary Fibrosis (IPF)
interferon beta 1-a
Relapsing Remitting Multiple Sclerosis
BIIB033 (anti-LINGO-1 mAb)
Acute Optic Neuritis
90-Y-ibritumomab tiuxetan
Lymphoma
Yttrium-ibritumomab (Zevalin)
Lymphoma, Mantle-Cell
Mechanism of action of alefacept
Psoriasis
Levodopa
Parkinson Disease
Chemotherapy and Radioimmunotherapy
Non-Hodgkin Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Leqembi Lecanemab | Approved | Alzheimer Disease | Fast TrackBreakthrough | - |
Tofersen | Approved | ALS (SOD1) | OrphanFast TrackBreakthrough | |
Omaveloxolone | Phase 3 | Friedreich Ataxia | - | - |
SAGE-217 15/20 mg Oral Solution | Phase 3 | Postpartum Depression | - | - |
BIIB041 (Fampridine-SR) | Phase 3 | Multiple Sclerosis | - | - |
Litifilimab | Phase 3 | Lupus Erythematosus, Systemic | - | - |
peginterferon beta-1a | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Avonex | Phase 3 | Multiple Sclerosis | - | - |
Bardoxolone Methyl | Phase 3 | Alport Syndrome | - | - |
ALKS 8700 | Phase 3 | Relapsing Remitting Multiple Sclerosis | - | - |
Natalizumab (BG00002) | Phase 3 | Multiple Sclerosis | - | - |
BIIB017 (peginterferon beta-1a) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Interferon Beta-1a | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | - | - |
dimethyl fumarate | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
Interferon Ξ²-1a | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
Salanersen | Phase 3 | Muscular Atrophy, Spinal | - | - |
tonapofylline | Phase 3 | Renal Insufficiency | - | - |
Midazolam | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
BIIB041 (fampridine) | Phase 3 | Multiple Sclerosis, Remittent Progressive | - | - |
natalizumab | Phase 3 | Crohn's Disease | - | - |
BIIB019 (Daclizumab High Yield Process) | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
Diroximel fumarate | Phase 3 | Relapsing Forms of Multiple Sclerosis | - | - |
BG9418 (Interferon beta-1a) | Phase 3 | Active Ulcerative Colitis | - | - |
Glatiramer Acetate | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
BG00012 | Phase 3 | Multiple Sclerosis | - | - |
Anti-inflammatory drugs | Phase 3 | Rheumatoid Arthritis | - | - |
fampridine | Phase 3 | Multiple Sclerosis | - | - |
Felzartamab | Phase 3 | Primary Membranous Nephropathy | - | - |
BG00012 (dimethyl fumarate) | Phase 3 | Healthy | - | - |
lixivaptan | Phase 3 | Hyponatremia | - | - |
BG00002 (natalizumab) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Sertraline | Phase 3 | Depressive Disorder, Major | - | - |
Alefacept | Phase 3 | Chronic Plaque Psoriasis | - | - |
SAGE-217 | Phase 3 | Bipolar Disorder I | - | - |
Mycophenolate Mofetil (cellcept) | Phase 3 | Multiple Sclerosis | - | - |
Nusinersen | Phase 3 | Muscular Atrophy, Spinal | - | - |
Rituxan, Cyclophosphamide, Vincristine, Prednisone | Phase 3 | Immune Thrombocytopenic Purpura | - | - |
baricitinib treatment | Phase 3 | Rheumatoid Arthritis | - | - |
BIIB017 | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Omaveloxolone Ophthalmic Suspension 0.5% | Phase 2 | Corneal Endothelial Cell Loss | - | - |
exemestane (Aromasin) | Phase 2 | Breast Cancer | - | - |
trivalent seasonal influenza vaccine | Phase 2 | Relapsing-Remitting Multiple Sclerosis | - | - |
BIIB122 | Phase 2 | Parkinson Disease | - | - |
Methylprednisolone | Phase 2 | Graft Versus Host Disease | - | - |
Zevalin Radioimmunotherapy | Phase 2 | Lymphoma | - | - |
SAGE-324 | Phase 2 | Essential Tremor | - | - |
CHOP | Phase 2 | Non-Hodgkins Lymphoma | - | - |
Y Zevalin | Phase 2 | Lymphoma | - | - |
Zevalin | Phase 2 | Lymphoma | - | - |
90Y Zevalin | Phase 2 | Non-Hodgkins Lymphoma | - | - |
Tyruko Injectable Product | Phase 2 | Multiple Sclerosis | - | - |
Transitioning patients from cyclosporine to alefacept | Phase 2 | Psoriasis | - | - |
Ibritumomab Tiuxetan (Zevalin) | Phase 2 | Lymphoma | - | - |
BIIB080 | Phase 2 | Alzheimer Disease | OrphanFast TrackBreakthrough | - |
BIIB091 | Phase 2 | Relapsing Forms of Multiple Sclerosis | - | - |
Omaveloxolone capsules, 2.5 mg | Phase 2 | MItochondrial Myopathies | - | - |
Bardoxolone methyl oral capsule | Phase 2 | Chronic Kidney Diseases | - | - |
CNV1014802 | Phase 2 | Lumbosacral Radiculopathy | - | - |
BIIB104 | Phase 2 | Cognitive Impairment Associated With Schizophrenia | - | - |
Lumiliximab with FCR | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
BG9924 | Phase 2 | Rheumatoid Arthritis | - | - |
BIIB021 | Phase 2 | GIST | - | - |
BIIB041 (PR Fampridine) | Phase 2 | Multiple Sclerosis | - | - |
BG00010 | Phase 2 | Painful Lumbar Radiculopathy | - | - |
BIIB014 | Phase 2 | Parkinson's Disease | - | - |
BIIB112 | Phase 2 | X-Linked Retinitis Pigmentosa | - | - |
Ad.hIFN-Ξ² (BG00001, IDEC-201) | Phase 2 | Colorectal Carcinoma | - | - |
BIIB033 | Phase 2 | Multiple Sclerosis | - | - |
IDEC-114 | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
MOR202 | Phase 2 | Glomerulonephritis | - | - |
Omaveloxolone Ophthalmic Suspension 1.0% | Phase 2 | Inflammation and Pain Following Ocular Surgery | - | - |
BIIB033 100mg/Kg | Phase 2 | Acute Optic Neuritis | - | - |
Bardoxolone methyl capsules | Phase 2 | IgA Nephropathy | - | - |
BIIB111 | Phase 2 | Choroideremia | - | - |
Bardoxolone Methyl (RTA 402) | Phase 2 | Chronic Kidney Disease | - | - |
natalizumab IV | Phase 2 | Relapsing-Remitting Multiple Sclerosis | - | - |
BG00002-E (natalizumab high titer) | Phase 2 | Multiple Sclerosis | - | - |
tetanus diphtheria toxoids vaccine | Phase 2 | Relapsing Forms of Multiple Sclerosis | - | - |
Omaveloxolone Capsules (2.5 mg/capsule) | Phase 2 | Melanoma | - | - |
Baminercept alfa 1 | Phase 2 | Rheumatoid Arthritis | - | - |
BIIB074 | Phase 2 | Primary Inherited Erythromelalgia | - | - |
Omaveloxolone Capsules, 300 mg | Phase 2 | Friedreich Ataxia | - | - |
Omaveloxolone Lotion 0.5% | Phase 2 | Breast Cancer | - | - |
Bardoxolone methyl (amorphous dispersion) | Phase 2 | Renal Insufficiency, Chronic | - | - |
RTA 402 (Bardoxolone Methyl) | Phase 2 | Diabetic Nephropathy | - | - |
BIIB059 (litifilimab) | Phase 2 | Systemic Lupus Erythematosus | - | - |
BG00011 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | - | - |
interferon beta 1-a | Phase 2 | Relapsing Remitting Multiple Sclerosis | - | - |
BIIB033 (anti-LINGO-1 mAb) | Phase 2 | Acute Optic Neuritis | - | - |
90-Y-ibritumomab tiuxetan | Phase 2 | Lymphoma | - | - |
Yttrium-ibritumomab (Zevalin) | Phase 2 | Lymphoma, Mantle-Cell | - | - |
Mechanism of action of alefacept | Phase 2 | Psoriasis | - | - |
Levodopa | Phase 2 | Parkinson Disease | - | - |
Chemotherapy and Radioimmunotherapy | Phase 2 | Non-Hodgkin Lymphoma | - | - |
Alzheimer Disease
2 drugs in this indication
Alzheimer's disease
2 drugs in this indication
C3G or Primary IC-MPGN in adolescents
2 drugs in this indication
ALS (SOD1)
1 drug in this indication
multiple myeloma
1 drug in this indication
Systemic Lupus Erythematosus
1 drug in this indication
Dravet Syndrome
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown β the signals behind the verdict
Frequently asked questions
What is in Biogen Inc.'s drug pipeline?β
CatalystAlert tracks 94 drug candidates in Biogen Inc.'s (BIIB) pipeline across Phase 3, Phase 2, Approved. Its lead program is Omaveloxolone (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Biogen Inc.'s next FDA catalyst?β
Biogen Inc.'s (BIIB) next tracked catalyst is a Phase 3 expected October 20, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BIIB biotech catalysts?β
Add BIIB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Biogen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.